Anju Showcases Advanced eClinical Suite at DIA Global Annual Meeting 2024

FORT LAUDERDALE, Fla., June 17, 2024 /PRNewswire/ — Anju Software, a trailblazer in comprehensive data and information management solutions for the life sciences industry, is proud to announce its participation in the DIA Global Annual Meeting at the San Diego Convention Center on June 17th-19th. Anju will display its advanced eClinical suite, including TrialMaster and CTMS, at booth #1710, underscoring its dedication to evolving clinical research through innovative technology.

The DIA Global Annual Meeting 2024 will bring together top innovators and thought leaders in the life sciences sector for networking, knowledge sharing, and showcasing the latest advancements in clinical research. Anju is proud to participate in this prestigious event, highlighting our dedication to providing state-of-the-art solutions that empower pharmaceutical, biotech, and medical device companies, as well as CROs, to enhance operations, ensure compliance, and achieve superior clinical trial outcomes.

“Anju is dedicated to advancing clinical research through innovative eClinical solutions and partnerships,” said Mike Loftus VP of the CRO Partner Program at Anju. “Our participation in the DIA Global Annual Meeting emphasizes our commitment to providing tools that drive efficiency, compliance, and productivity in clinical trials.”

At the conference, Anju’s team will be on hand to discuss how the company’s innovative solutions optimize clinical trial processes, boost operational efficiency, and maintain stringent regulatory compliance. From trial planning to execution, Anju offers a comprehensive suite of tools tailored to meet the complex needs of modern clinical trials. This includes leveraging advanced Data Science to enhance trial planning, improve feasibility assessments, and promote diversity and inclusion in patient recruitment strategies.

Don’t miss the chance to visit Anju’s booth #1710 at the DIA Global Annual Meeting 2024 and learn how Anju’s innovative eClinical solutions can elevate your organization’s performance.
For more information about Anju Software and its comprehensive suite of software solutions, please visit https://www.anjusoftware.com.

About Anju Software:
Anju Software is a customer-first organization providing adaptable life science solutions for clinical research, medical affairs, and data science. TrialMaster, IRMS MAX, and TA Scan, the company’s flagship products, lead the way in reducing complexities in the drug and device discovery and commercialization process. Anju is a portfolio company of Abry Partners serving the worldwide pharmaceutical, biotech and contract research Life Sciences markets.

For media inquiries, please contact:
John F. Kouten
JFK Communications, Inc.
+1 609.241.7352
jfkouten@jfkhealth.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/anju-showcases-advanced-eclinical-suite-at-dia-global-annual-meeting-2024-302174607.html

SOURCE Anju Software

Staff

Recent Posts

AI-Era Position Statement to Protect the Integrity of Healthcare, Technology, and Services Benchmarking published by Black Book Research

Black Book outlines an AI-era integrity architecture for healthcare benchmarking, instrumentation hardening, tiered verification, real-time…

20 hours ago

New employee representative on the Board of Directors of Novo Nordisk A/S

Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since…

20 hours ago

Embers to Empowerment: The Womb Room Reopens in Govans, Expanding Community-Centered Perinatal Care After Hampden Fire

Baltimore, Maryland, Jan. 31, 2026 (GLOBE NEWSWIRE) -- After sustaining water damage during the massive…

20 hours ago

Oxford Healthspan to Introduce New Primeadine® GF Powder Through a ‘Longevity Shot’ Experience During Grammy Week in Los Angeles

Science-Backed Spermidine Ritual Brings Cellular Renewal to a High-Performance Cultural Moment Primeadine Longevity Shot Primeadine…

20 hours ago

Enzon Announces Commencement of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock in Connection With Viskase Merger

CRANFORD, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or…

20 hours ago

Park Dental Partners Announces Dates for Fourth Quarter and Full Year 2025 Earnings Release and Conference Call

MINNEAPOLIS, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Park Dental Partners, Inc. (NASDAQ: PARK), a leading…

20 hours ago